Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) trades at $14.00 with AI Score 50/100 (Grade B). Taisho Pharmaceutical Holdings Co. , Ltd. Market cap: $18.1B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for TAIPY: TAIPY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TAIPY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TAIPY: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) Healthcare & Pipeline Overview
Taisho Pharmaceutical Holdings Co., Ltd., a Japanese multinational, develops, manufactures, and markets OTC and prescription drugs. With a strong presence in Asia, the company's diverse portfolio spans energy drinks, cold remedies, and prescription medications, positioning it as a key player in the global healthcare market with a $18.1B market capitalization.
What Is the Investment Thesis for TAIPY?
Taisho Pharmaceutical Holdings Co., Ltd. presents a compelling investment thesis based on its established market position, diversified product portfolio, and growth opportunities in both OTC and prescription drug markets. The company's strong presence in the self-medication market, particularly in Asia, provides a stable revenue stream. Key value drivers include the continued growth of its flagship brands like Lipovitan and Pabron, as well as the successful development and launch of new prescription drugs. With a P/E ratio of 37.03 and a profit margin of 6.3%, Taisho's financial performance reflects its ability to generate profits in a competitive industry. Upcoming catalysts include potential regulatory approvals for pipeline drugs and expansion into new geographic markets. Potential risks include increasing competition from generic drug manufacturers and regulatory changes affecting drug pricing and reimbursement.
Based on FMP financials and quantitative analysis
TAIPY Key Highlights
Market capitalization of $18.1B, reflecting its significant presence in the pharmaceutical industry.
- P/E ratio of 37.03, indicating investor expectations of future earnings growth.
- Gross margin of 59.0%, showcasing efficient cost management and strong pricing power.
- Profit margin of 6.3%, demonstrating profitability in a competitive market.
- Beta of 0.44, suggesting lower volatility compared to the overall market.
Who Are TAIPY's Competitors?
TAIPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AIHLF Adcock Ingram Holdings Limited | $3.50 | +0.00% | $624M | 48 |
| ESALY Eisai Co., Ltd. | $61.51 | -2.11% | $17.6B | 57 |
| IHHHF IHH Healthcare Berhad | $1.71 | +0.00% | $15.1B | 51 |
| INVVY Indivior PLC | $21.85 | +0.00% | $3.01B | 47 |
| IPSEF Ipsen S.A. | $113.13 | +0.00% | $9.36B | 53 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TAIPY's Key Strengths?
Strong brand recognition in Japan and Southeast Asia.
- Diversified product portfolio across OTC and prescription drugs.
- Established distribution network.
- Commitment to research and development.
What Are TAIPY's Weaknesses?
Limited presence in developed markets outside of Asia.
- Reliance on certain key products for revenue generation.
- Exposure to regulatory risks and pricing pressures.
- Relatively low profit margin compared to some competitors.
What Could Drive TAIPY Stock Higher?
Potential regulatory approvals for new prescription drugs in the pipeline.
- Expansion of the OTC product portfolio in key markets.
- Strategic partnerships and collaborations to enhance drug development and market access.
- Increasing demand for self-medication and OTC products.
- Launch of new marketing campaigns to promote key brands.
What Are the Key Risks for TAIPY?
Increasing competition from generic drug manufacturers.
- Regulatory changes affecting drug pricing and reimbursement.
- Patent expirations and loss of exclusivity.
- Economic downturns affecting consumer spending on healthcare products.
- Currency fluctuations affecting international revenue and profitability.
What Are the Growth Opportunities for TAIPY?
- Expansion in Southeast Asia: Taisho can leverage its existing presence in Southeast Asia to further expand its market share. The region's growing population, rising healthcare expenditure, and increasing awareness of self-medication present significant opportunities. The Southeast Asian pharmaceutical market is projected to reach $44 billion by 2027, offering a substantial growth runway for Taisho. By introducing new products and strengthening its distribution network, Taisho can capitalize on this expanding market.
- New Product Development: Taisho's pipeline of drugs targeting central nervous system disorders, infectious diseases, metabolic diseases, and orthopedic disorders represents a significant growth opportunity. Successful development and commercialization of these products could drive revenue growth and enhance the company's competitive position. The global market for central nervous system drugs is expected to reach $150 billion by 2028, providing a substantial target market for Taisho's pipeline products.
- Strategic Acquisitions: Taisho can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquiring companies with complementary products or technologies could accelerate growth and enhance the company's competitive advantage. The pharmaceutical industry is characterized by frequent mergers and acquisitions, providing ample opportunities for Taisho to pursue inorganic growth.
- Increased Focus on OTC Market: The global OTC market is experiencing steady growth, driven by increasing consumer awareness of self-care and the availability of a wider range of OTC products. Taisho can capitalize on this trend by expanding its OTC product portfolio and strengthening its marketing efforts. The global OTC market is projected to reach $220 billion by 2028, offering a significant growth opportunity for Taisho.
- Partnerships and Collaborations: Taisho can form partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to accelerate drug development, expand market access, and enhance its technological capabilities. Collaborations can provide access to new technologies, expertise, and resources, enabling Taisho to compete more effectively in the global pharmaceutical market. Strategic alliances can also help Taisho mitigate risks and share costs associated with drug development.
What Are TAIPY's Competitive Advantages?
- Established Brand Recognition: Taisho has a long history and strong brand recognition, particularly in Japan and Southeast Asia.
- Diversified Product Portfolio: The company offers a wide range of OTC and prescription drugs, reducing its reliance on any single product.
- Strong Distribution Network: Taisho has a well-established distribution network, enabling it to reach a wide range of customers.
- Research and Development Capabilities: The company invests in research and development to develop new and innovative products.
What Does TAIPY Do?
Founded in 1912 and headquartered in Tokyo, Japan, Taisho Pharmaceutical Holdings Co., Ltd. has evolved into a prominent global pharmaceutical company. Initially focused on manufacturing and distributing pharmaceutical products in Japan, the company expanded its operations internationally through strategic acquisitions and organic growth. Taisho operates through two primary segments: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication segment offers a wide array of OTC drugs, quasi-drugs, food products, and general medical supplies, including the popular Lipovitan energy drink series, Pabron cold remedies, and RiUP hair re-growth treatments. The Prescription Pharmaceutical segment focuses on ethical drugs, such as Edirol for osteoporosis, Clarith for bacterial infections, and Lusefi for type 2 diabetes. Taisho's commitment to research and development is evident in its pipeline of products targeting central nervous system disorders, infectious diseases, metabolic diseases, and orthopedic disorders. The company also supplies raw materials for pharmaceuticals and offers health foods and skincare products, demonstrating its diversified approach to healthcare. Taisho's geographic reach extends across Asia, Europe, and Latin America, with a significant presence in Japan and Southeast Asia. The company faces competition from both global pharmaceutical giants and regional players, but its established brands and diversified product portfolio provide a competitive edge.
What Products and Services Does TAIPY Offer?
- Researches and develops over-the-counter (OTC) drugs.
- Manufactures and markets OTC drugs and prescription pharmaceutical products.
- Distributes and sells OTC drugs and prescription pharmaceutical products in Japan and internationally.
- Offers Lipovitan series of energy drinks.
- Provides Pabron series of cold remedies and sinus treatments.
- Sells RiUP series of hair re-growth treatment products.
- Offers ethical drugs, including Edirol for osteoporosis and Clarith for bacterial infections.
How Does TAIPY Make Money?
- Develops and manufactures pharmaceutical products.
- Sells products through both the Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments.
- Generates revenue from OTC drugs, prescription drugs, and raw materials.
- Focuses on both domestic and international markets.
What Industry Does TAIPY Operate In?
Taisho Pharmaceutical Holdings Co., Ltd. operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for innovative treatments. Taisho competes with both large multinational corporations and smaller regional players. The company's focus on both OTC and prescription drugs allows it to capitalize on different market segments and diversify its revenue streams.
Who Are TAIPY's Key Customers?
- Consumers seeking over-the-counter medications for self-treatment.
- Patients requiring prescription drugs for various medical conditions.
- Healthcare providers prescribing medications to patients.
- Retail pharmacies and drug stores selling pharmaceutical products.
Key Financial Metrics
Return on equity for Taisho Pharmaceutical Holdings Co., Ltd. stands at 2.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.0%, showing how much profit it generates from its asset base. TAIPY trades at a trailing price-to-earnings ratio of 37.03, above the Healthcare sector average of ~23x. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) Valuation Context
Valued at $18.1B, TAIPY is classified as a large-cap stock. Relative to its peer group, TAIPY's quantitative score of 50/100 is roughly in line with the peer average of 51/100.
Company Profile
Taisho Pharmaceutical Holdings Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Akira Uehara. TAIPY has traded publicly since 2021.
Financial Health
Taisho Pharmaceutical Holdings Co., Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.47 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Taisho Pharmaceutical Holdings Co., Ltd. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 8.3% above estimates on average.
TAIPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Strong brand recognition in Japan and Southeast Asia.
- Diversified product portfolio across OTC and prescription drugs.
- Established distribution network.
- Commitment to research and development.
Bear Case
- Limited presence in developed markets outside of Asia.
- Reliance on certain key products for revenue generation.
- Exposure to regulatory risks and pricing pressures.
- Relatively low profit margin compared to some competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
TAIPY Latest News
No recent news available for TAIPY.
TAIPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TAIPY.
Price Targets
Wall Street price target analysis for TAIPY.
TAIPY MoonshotScore
What does this score mean?
The MoonshotScore rates TAIPY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Akira Uehara
CEO
Akira Uehara serves as the CEO of Taisho Pharmaceutical Holdings Co., Ltd. His career within the pharmaceutical industry spans several decades, marked by a deep understanding of both the Japanese and global markets. Prior to his role as CEO, Uehara held various leadership positions within Taisho, overseeing strategic planning, product development, and international expansion initiatives. His expertise lies in navigating the complex regulatory landscape of the pharmaceutical sector and driving innovation in drug development.
Track Record: Under Akira Uehara's leadership, Taisho Pharmaceutical has focused on expanding its presence in the OTC drug market and strengthening its research and development pipeline. Key milestones include the successful launch of new OTC products and the advancement of several prescription drug candidates through clinical trials. Uehara has also overseen strategic acquisitions aimed at expanding Taisho's geographic reach and product portfolio. He manages 8784 employees.
Taisho Pharmaceutical Holdings Co., Ltd. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. TAIPY, as an ADR, allows U.S. investors to trade shares of Taisho Pharmaceutical Holdings Co., Ltd. on the OTC market without the complexities of cross-border transactions. The depositary bank purchases shares in the company's home market (Tokyo) and issues ADRs representing those shares.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: TAIP
TAIPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. Information availability is often limited, making due diligence challenging compared to exchange-listed companies.
- OTC Tier: OTC Other
- Limited liquidity and trading volume.
- Lack of regulatory oversight and financial disclosure.
- Potential for price manipulation and fraud.
- Higher bid-ask spreads and transaction costs.
- Increased volatility and execution risks.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's risk factors and potential liabilities.
- Check for any legal or regulatory issues involving the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established history as a pharmaceutical company.
- Presence in both OTC and prescription drug markets.
- Global operations and distribution network.
- Commitment to research and development.
- Listing on the Tokyo Stock Exchange (home market).
What Investors Ask About Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) — Healthcare
What does the AI Score mean for TAIPY?
TAIPY holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Taisho Pharmaceutical Holdings Co., Ltd. is a global pharmaceutical company based in Japan, focusing on both over-the-counter (OTC) and prescription drugs. With a history spanning over a century …
What does Taisho Pharmaceutical Holdings Co., Ltd. do?
Taisho Pharmaceutical Holdings Co., Ltd. is a global pharmaceutical company that researches, develops, manufactures, and markets a wide range of over-the-counter (OTC) and prescription pharmaceutical products. Its business is divided into Self-Medication and Prescription Pharmaceutical segments.
What are the main risks for TAIPY?
Taisho Pharmaceutical Holdings Co., Ltd. faces several risks, including increasing competition from generic drug manufacturers, regulatory changes affecting drug pricing and reimbursement, and patent expirations. The company is also exposed to economic downturns that could affect consumer spending on healthcare products. Currency fluctuations can impact international revenue and profitability.
What are the key factors to evaluate for TAIPY?
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) holds an AI score of 50/100 (moderate). presents a compelling investment thesis based on its established market position, diversified product portfolio, and growth opportunities in both OTC and prescription drug markets. Not financial advice.
How frequently does TAIPY data refresh on this page?
TAIPY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TAIPY's recent stock price performance?
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition in Japan and Southeast Asia. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TAIPY overvalued or undervalued right now?
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TAIPY before investing?
Before investing in Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TAIPY to a portfolio?
Key strength of Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY): Strong brand recognition in Japan and Southeast Asia. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.